Medical devices, healthcare technology and the business of care
PMA approval · P200048

IsoPSA Assay

Cleveland Diagnostics, Inc. · Decision date Nov 28, 2025

FDA DECISIONP200048

What did the FDA approve?

FDA records P200048 as an original PMA application. The recorded decision is approval, dated Nov 28, 2025.

FDA approval order statement

Approval for the IsoPSA Assay.The IsoPSA Assay is an in vitro test system that combines the results of total Prostate Specific Antigen (PSA) (Elecsys, Roche Diagnostics) and free PSA (Elecsys, Roche Diagnostics) from partitioned heparinized plasma into a single numerical index. The IsoPSA Assay is indicated for use in conjunction with other patient information to aid in detection of high-grade prostate cancer (Grade Group >= 2; Gleason score >= 7) in men >= 50 years of age, with total PSA levels >= 4.0 to =< 10.0 ng/mL for whom a biopsy is being considered by a urologist based on current standard of care, before consideration of IsoPSA Assay results.Prostatic biopsy is required for the diagnosis of cancer.
Regulatory pathway
Original PMA
Clinical specialty
Immunology
Decision date
Nov 28, 2025

FDA source record

Regulatory record facts

Identifier
P200048
Regulatory pathway
Premarket approval application
Product code
QRF
Decision code
APPR
Decision date
Nov 28, 2025
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Multi-analyte test system with algorithmic analysis for detection of prostate cancer.

Product code
QRF
FDA device class
3

The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.

FDA decision timeline

  1. P200048 received

    Application receipt date recorded by FDA.

  2. P200048 · FDA decision

    APPR

Timeline entries are records held by MedtechLedger for P200048. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P200048

Product / regulatory recordCompanyPathwayDecision dateSource
IsoPSA AssayP200048/S001
Cleveland Diagnostics, Inc.PMA supplementJul 28, 2026FDA

Explore the linked device profile

Other records with product code QRF

Product / regulatory recordCompanyPathwayDecision dateSource
4Kscore TestP190022/S003
Opko Health, Inc.PMA supplementJul 25, 2025FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Cleveland Diagnostics, Inc.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
3615 Superior Ave., Suite 4407b, Cleveland, OH, 44114

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records